The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation

Megan McNamara, Christopher Sweeney, Emmanuel S. Antonarakis, Andrew J. Armstrong

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations


Background: Until 2015, androgen deprivation therapy (ADT) alone was the standard-of-care for metastatic hormone-sensitive prostate cancer (mHSPC). In 2015, the CHAARTED and STAMPEDE-Docetaxel studies demonstrated marked survival benefit with the addition of docetaxel to ADT in the mHSPC setting, leading to a change in the standard-of-care for mHSPC. The recent LATITUDE and STAMPEDE-Abiraterone trials showed similar substantial improvement in survival with the addition of abiraterone plus prednisone to ADT in this space. Methods: We conducted a review of the randomized phase III studies that have investigated either the addition of docetaxel or abiraterone to ADT in patients with mHSPC. Results: We describe the study designs, key eligibility criteria, and key results for the CHAARTED, STAMPEDE-Docetaxel, GETUG-AFU 15, LATITUDE, and STAMPEDE-Abiraterone clinical trials. We compare the data for abiraterone/prednisone plus ADT in mHSPC with the evidence for docetaxel plus ADT in these patients. Finally, we discuss several factors that should be considered when choosing between docetaxel/ADT or abiraterone/prednisone/ADT in mHSPC. Conclusions: The management of mHSPC is evolving. Abiraterone plus prednisone in addition to ADT has emerged as an alternative standard-of-care to docetaxel plus ADT, and ongoing trials should clarify whether combination vs. sequential approaches with AR-targeting agents and taxane chemotherapy are preferred for initial management in the hormone-sensitive setting.

Original languageEnglish (US)
Pages (from-to)306-318
Number of pages13
JournalProstate Cancer and Prostatic Diseases
Issue number3
StatePublished - Sep 1 2018
Externally publishedYes

Bibliographical note

Funding Information:
Funding MM: Research funding to institution from Bayer, Janssen, Agensys, Seattle Genetics, Clovis, Astrazeneca. AJA: Research funding to institution from Bayer, Janssen, Medivation/Astellas/ Pfizer, Dendreon, Sanofi Aventis, Gilead, Genentech/Roche, Novartis. Consulting with Janssen, Medivation/Pfizer/Astellas. Speaker for Bayer, Dendreon, Sanofi Aventis. CS: Research funding to institution from Astellas, Janssen, Sotio, Sanofi. Paid consultant to Astellas, Bayer, Genentech, Janssen, Pfizer, Sanofi. ESA: Paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Mediva-tion, and ESSA. Research funding to institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, and Tokai. Co-inventor of a biomarker technology that has been licensed to Tokai and Qiagen.

Publisher Copyright:
© 2017, The Author(s), under exclusive licence to Macmillan Publishers Limited, part of Springer Nature.


Dive into the research topics of 'The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation'. Together they form a unique fingerprint.

Cite this